ISRCTN76463647
Completed
Not Applicable
Optimising thromboembolic and stroke prevention: a randomised controlled trial of pharmacist-managed oral anticoagulotherapy
Cité de la Santé de Laval (Canada)0 sites500 target enrollmentSeptember 5, 2005
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Thromboembolism and stroke
- Sponsor
- Cité de la Santé de Laval (Canada)
- Enrollment
- 500
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. The patient is referred to the Pharmacy Managed Anticoagulation Service (PMAS) with a prescription of warfarin for at least six months
- •2\. The patient is aged 18 years and older, either sex
- •3\. The patient agrees to go to the Cité de la Santé de Laval, the Centre Hospitalier Ambulatoire Régional de Laval, or one of the four Laval Centre Local de Services Communautaire for blood drawing during participation in the study (six months)
- •4\. The patient lives in the Laval area
- •5\. The patient is able to read and speak French or English
- •6\. The patient agrees to participate in the study and has signed the informed consent form
- •7\. The patient's treating physician has agreed to participate and has signed the informed consent form
- •8\. It is expected that the patient will be transferred to the treating physician
Exclusion Criteria
- •1\. The patient participates to another study
- •2\. The patient is referred to the PMAS for a pre\-admission
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prevention of Thromboembolic Events – European Registry in Venous ThromboembolismMedDRA - Venous ThromboembolismI82Other venous embolism and thrombosisDRKS00004795Daiichi-Sankyo Europe GmbH3,544
Recruiting
Phase 1
Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosisThromboprophylaxis in good and intermediate prognosis advanced germ cell tumorsMedDRA version: 20.0Level: LLTClassification code: 10075819Term: Testicular germ cell tumor Class: 10029104Therapeutic area: Diseases [C] - Male Urogenital Diseases [C12]Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2022-502426-41-00Institut Gustave Roussy387
Recruiting
Not Applicable
Pre-stroke awareness and antithrombotic use for atrial fibrillation in patients with acute ischemic stroke - Data from a multicenter hospital-based registryDiseases of the nervous systemKCT0000851Seoul National University Bundang Hospital3,145
Recruiting
Not Applicable
eiden Thrombosis Recurrence Risk Prevention: Tailored treatment after a first venous thromboembolism: (L-TRRiP study)NL-OMON54327eids Universitair Medisch Centrum1,600
Recruiting
Not Applicable
eiden Thrombosis Recurrence Risk Preventio<p>Venous thromboembolism (deep vein thrombosis and pulmonary embolism)</p>VTE10014523NL-OMON26314eiden University Medical Centre608